Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Leonard

Showing results (561-570 of 686) with videos related to

Pageof 69
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2003
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphomaJohn P Leonard, Morton Coleman, Jamie C Ketas, et al.
Blood|February 26, 2005
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomabJohn M Bennett, Mark S Kaminski, John P Leonard, et al.
Cancer|June 8, 2019
Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance)Kristie A Blum, Mei-Yin Polley, Sin-Ho Jung, et al.
Journal of Endourology|May 6, 2020
Dual-Energy Computed Tomography for Stone Type Assessment: A Pilot Study of Dual-Energy Computed Tomography with Five IndicesVadim Rudenko, Natalia Serova, Lida Kapanadze, et al.
Leukemia|March 21, 2003
Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002P M Navolanic, C-H Pui, R A Larson, et al.
Blood Advances|June 28, 2023
Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphomaW Richard Burack, Hongli Li, Diana Adlowitz, et al.
Journal of the National Cancer Institute|January 2, 2017
Recommendations for Clinical Trial Development in Follicular LymphomaKami Maddocks, Paul M Barr, Bruce D Cheson, et al.
JCO Oncology Practice|December 6, 2024
Comparison of Survivorship Care Guidelines for Patients With Lymphoma: Recommendations for Harmonization and Future Research AgendaBryan Valcarcel, Kerry J Savage, Brian K Link, et al.
Nature Neuroscience|November 23, 2023
A dynamic sequence of visual processing initiated by gaze shiftsPhilip R L Parker, Dylan M Martins, Emmalyn S P Leonard, et al.
Blood|August 24, 2021
Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCLPeter Martin, Nancy L Bartlett, Julio C Chavez, et al.
Pageof 69

Showing results (561-570 of 686) with videos related to

Sort By:
Pageof 69
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 3, 2003
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphomaJohn P Leonard, Morton Coleman, Jamie C Ketas, et al.
Blood|February 26, 2005
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomabJohn M Bennett, Mark S Kaminski, John P Leonard, et al.
Cancer|June 8, 2019
Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance)Kristie A Blum, Mei-Yin Polley, Sin-Ho Jung, et al.
Journal of Endourology|May 6, 2020
Dual-Energy Computed Tomography for Stone Type Assessment: A Pilot Study of Dual-Energy Computed Tomography with Five IndicesVadim Rudenko, Natalia Serova, Lida Kapanadze, et al.
Leukemia|March 21, 2003
Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002P M Navolanic, C-H Pui, R A Larson, et al.
Blood Advances|June 28, 2023
Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphomaW Richard Burack, Hongli Li, Diana Adlowitz, et al.
Journal of the National Cancer Institute|January 2, 2017
Recommendations for Clinical Trial Development in Follicular LymphomaKami Maddocks, Paul M Barr, Bruce D Cheson, et al.
JCO Oncology Practice|December 6, 2024
Comparison of Survivorship Care Guidelines for Patients With Lymphoma: Recommendations for Harmonization and Future Research AgendaBryan Valcarcel, Kerry J Savage, Brian K Link, et al.
Nature Neuroscience|November 23, 2023
A dynamic sequence of visual processing initiated by gaze shiftsPhilip R L Parker, Dylan M Martins, Emmalyn S P Leonard, et al.
Blood|August 24, 2021
Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCLPeter Martin, Nancy L Bartlett, Julio C Chavez, et al.
Pageof 69